EA201071137A1 - Способы лечения - Google Patents

Способы лечения

Info

Publication number
EA201071137A1
EA201071137A1 EA201071137A EA201071137A EA201071137A1 EA 201071137 A1 EA201071137 A1 EA 201071137A1 EA 201071137 A EA201071137 A EA 201071137A EA 201071137 A EA201071137 A EA 201071137A EA 201071137 A1 EA201071137 A1 EA 201071137A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
antibody
relates generally
fabs
Prior art date
Application number
EA201071137A
Other languages
English (en)
Russian (ru)
Inventor
Фредрик Э. Харгрив
Джампьетро Вентреска
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41114741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201071137A1 publication Critical patent/EA201071137A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201071137A 2008-03-28 2009-03-27 Способы лечения EA201071137A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4036308P 2008-03-28 2008-03-28
PCT/US2009/038509 WO2009120927A2 (en) 2008-03-28 2009-03-27 Methods of treatment

Publications (1)

Publication Number Publication Date
EA201071137A1 true EA201071137A1 (ru) 2011-04-29

Family

ID=41114741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071137A EA201071137A1 (ru) 2008-03-28 2009-03-27 Способы лечения

Country Status (14)

Country Link
US (3) US9834600B2 (https=)
EP (1) EP2274009B1 (https=)
JP (4) JP5917143B2 (https=)
KR (1) KR20100134702A (https=)
CN (1) CN102026660A (https=)
AU (1) AU2009228163B2 (https=)
BR (1) BRPI0910854A2 (https=)
CA (1) CA2719786A1 (https=)
EA (1) EA201071137A1 (https=)
ES (1) ES2441945T3 (https=)
IL (1) IL208354A0 (https=)
MX (1) MX2010010667A (https=)
WO (1) WO2009120927A2 (https=)
ZA (1) ZA201006648B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
WO2009120927A2 (en) * 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
KR20110071064A (ko) 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
UA122670C2 (uk) 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
TWI799417B (zh) 2017-05-26 2023-04-21 英商葛蘭素史克智慧財產發展有限公司 生物製藥組成物及相關方法
EP4192453A4 (en) * 2020-08-05 2024-11-13 Areteia Therapeutics, Inc. USE OF DEXPRAMIPEXOLE TO TREAT MODERATE TO SEVERE ASTHMA
WO2026053108A1 (en) * 2024-09-03 2026-03-12 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
ZA898322B (en) 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
AU1289795A (en) 1993-11-19 1995-06-06 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
WO1996021000A2 (en) 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
TR200001117T2 (tr) * 1997-10-22 2000-09-21 Ponikau Jens Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler.
WO2001012646A1 (en) 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies
US20030017169A1 (en) * 2000-12-29 2003-01-23 Sidney Pestka Controlled release systems for polymers
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7339507B1 (en) * 2006-09-13 2008-03-04 Jiun-In Guo Device for video decoding
WO2008073458A2 (en) * 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2009120927A2 (en) 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
US8926631B2 (en) 2010-08-06 2015-01-06 MoMelan Technologies, Inc. Methods for preparing a skin graft without culturing or use of biologics
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂

Also Published As

Publication number Publication date
JP2017048224A (ja) 2017-03-09
EP2274009A2 (en) 2011-01-19
CN102026660A (zh) 2011-04-20
US20110020339A1 (en) 2011-01-27
JP5917143B2 (ja) 2016-05-11
JP2014240408A (ja) 2014-12-25
JP2011516422A (ja) 2011-05-26
JP6457463B2 (ja) 2019-01-23
AU2009228163A1 (en) 2009-10-01
EP2274009A4 (en) 2012-01-25
JP6069267B2 (ja) 2017-02-01
MX2010010667A (es) 2010-11-09
ZA201006648B (en) 2011-07-27
CA2719786A1 (en) 2009-10-01
KR20100134702A (ko) 2010-12-23
WO2009120927A3 (en) 2009-12-30
AU2009228163B2 (en) 2012-08-30
US11325972B2 (en) 2022-05-10
US20180057582A1 (en) 2018-03-01
BRPI0910854A2 (pt) 2015-10-06
IL208354A0 (en) 2010-12-30
ES2441945T3 (es) 2014-02-07
US9834600B2 (en) 2017-12-05
WO2009120927A2 (en) 2009-10-01
EP2274009B1 (en) 2013-11-13
US20200071395A1 (en) 2020-03-05
JP2019065029A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
EA201071137A1 (ru) Способы лечения
WO2013037484A3 (en) Anti-aplhabetatcr antibody
NZ621170A (en) Anti-human cd52 immunoglobulins
JO3097B1 (ar) الأجسام المضادة c-Met
NZ611076A (en) Anti-ngf compositions and use thereof
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
WO2010039900A3 (en) Non-human mammals for the production of chimeric antibodies
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
MY157173A (en) Modified humanised anti-interleukin-18
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
EA201301295A1 (ru) Композиции антител против cgrp и их применение
EA200802168A1 (ru) Гуманизированное антитело к с-kit
AR079944A1 (es) Anticuerpo neutralizante de la actividad de un anticoagulante
NZ600262A (en) Anti-her3 antibodies and uses thereof
NZ611269A (en) Neutralizing anti-ccl20 antibodies
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
NZ595235A (en) Compositions and methods for increasing muscle growth
NZ610734A (en) Human antibodies to the glucagon receptor
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2013188864A3 (en) Anti-cd22 anti-idiotypic antibodies and uses thereof
WO2012109280A3 (en) Apoe immunotherapy
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders